Overall disease assessment outcomes and outcome measures used in studies of Behçet syndrome. Numerals in parentheses indicate references.
| RCT*, n = 25 | Other**, n = 150 | Biomarker, n = 73 | Overall, n = 248 | |
|---|---|---|---|---|
| Behçet’s Disease Current Activity Form (BDCAF) (7–30) | — | 17 | 7 | 24 |
| Clinical Disease Activity Index (32) | — | 1 | — | 1 |
| Clinical Manifestations Index (33,34,35) | 1 | 2 | — | 3 |
| Iranian BD Dynamic Activity Measure (18,20,31,37) | 1 | 3 | — | 4 |
| 1994 Criteria for Disease Activity of BD (36) | — | 1 | — | 1 |
| Activity, self-defined (38–87) | — | 4 | 46 | 50 |
| Activity, not defined (88–91) | — | 4 | 4 | |
| Krause’s total severity score (38,46,51,57,104–114) | — | 11 | 4 | 15 |
| Severity (self-defined) (12,32,60,65,82,115–117) | 1 | 2 | 6 | 9 |
| Relapse (30,119–121) | — | 2 | 1 | 3 |
| Response (complete/partial) (30,122,123) | — | 3 | 3 | |
| Remission (complete/partial) (71,72,90,119–121) | 1 | 1 | 4 | 6 |
| Physicians Global Assessment (18,211) | — | 2 | — | 2 |
| BD Quality of Life (19,124,125) | — | 3 | — | 3 |
| Proportion of patients remaining on treatment (30) | — | 1 | — | 1 |
| Development of major organ involvement (98,122,174) | 1 | 2 | — | 3 |
| Death (92–103) | — | 11 | — | 11 |
↵* Only 4 of the 25 RCT used an outcome measure for overall disease assessment.
↵** The outcome measures used in uncontrolled interventional studies, cohorts, and case control studies are given together under the “other studies” column. A total of 66 outcome measures for overall disease assessment were used in these 150 studies. Similarly, biomarker studies and generic association studies are given together under the “Biomarker” column. RCT: randomized controlled trial; BD: Behçet disease.